ReShape Lifesciences Announces 1-for-25 Reverse Stock Split
ReShape Lifesciences (NASDAQ: RSLS) has announced a 1-for-25 reverse stock split of its common stock, effective for trading on May 9, 2025. Following the split, every 25 shares of outstanding common stock will be consolidated into one share. The company will make proportional adjustments to outstanding warrants, stock options, and convertible preferred stock. Any fractional shares will be rounded up to the nearest whole share.
The reverse split was approved by stockholders on April 1, 2025. The company's transfer agent, Equiniti Trust Company, will provide instructions for exchanging existing certificates. The new CUSIP number will be 76090R408. The number of authorized shares under the company's certificate of incorporation will remain unchanged.
ReShape Lifesciences (NASDAQ: RSLS) ha annunciato un raggruppamento azionario inverso 1-per-25 delle sue azioni ordinarie, che entrerà in vigore per la negoziazione il 9 maggio 2025. Dopo il raggruppamento, ogni 25 azioni ordinarie in circolazione saranno consolidate in una sola azione. La società apporterà adeguamenti proporzionali ai warrant in circolazione, alle opzioni azionarie e alle azioni privilegiate convertibili. Eventuali frazioni di azioni saranno arrotondate per eccesso alla quota intera più vicina.
Il raggruppamento è stato approvato dagli azionisti il 1° aprile 2025. L'agente di trasferimento della società, Equiniti Trust Company, fornirà le istruzioni per lo scambio dei certificati esistenti. Il nuovo numero CUSIP sarà 76090R408. Il numero di azioni autorizzate ai sensi dello statuto della società rimarrà invariato.
ReShape Lifesciences (NASDAQ: RSLS) ha anunciado una consolidación inversa de acciones 1 por 25 de sus acciones comunes, que entrará en vigor para la negociación el 9 de mayo de 2025. Tras la consolidación, cada 25 acciones comunes en circulación se combinarán en una sola acción. La compañía realizará ajustes proporcionales a los warrants en circulación, opciones sobre acciones y acciones preferentes convertibles. Cualquier fracción de acción se redondeará al número entero más cercano hacia arriba.
La consolidación inversa fue aprobada por los accionistas el 1 de abril de 2025. El agente de transferencia de la compañía, Equiniti Trust Company, proporcionará instrucciones para el intercambio de los certificados existentes. El nuevo número CUSIP será 76090R408. El número de acciones autorizadas según el certificado de incorporación de la compañía permanecerá sin cambios.
ReShape Lifesciences (NASDAQ: RSLS)는 1대 25 역병합을 2025년 5월 9일부터 거래에 적용한다고 발표했습니다. 역병합 후 기존 보통주 25주가 1주로 통합됩니다. 회사는 발행된 워런트, 스톡옵션, 전환 우선주에 대해 비례 조정을 실시할 예정입니다. 소수점 이하 주식은 가장 가까운 정수 주식으로 올림 처리됩니다.
이 역병합은 2025년 4월 1일 주주들의 승인을 받았습니다. 회사의 주식 이전 대리인인 Equiniti Trust Company가 기존 증서 교환 절차에 대한 안내를 제공할 것입니다. 새로운 CUSIP 번호는 76090R408입니다. 회사 정관에 따른 승인 주식 수는 변경되지 않습니다.
ReShape Lifesciences (NASDAQ: RSLS) a annoncé un regroupement d'actions inversé au ratio de 1 pour 25 de ses actions ordinaires, effectif à partir du 9 mai 2025. Après le regroupement, chaque groupe de 25 actions ordinaires en circulation sera consolidé en une seule action. La société procédera à des ajustements proportionnels sur les bons de souscription, options d'achat d'actions et actions privilégiées convertibles en circulation. Les fractions d'actions seront arrondies à l'action entière la plus proche vers le haut.
Le regroupement inversé a été approuvé par les actionnaires le 1er avril 2025. L'agent de transfert de la société, Equiniti Trust Company, fournira les instructions pour l'échange des certificats existants. Le nouveau numéro CUSIP sera 76090R408. Le nombre d'actions autorisées selon les statuts de la société restera inchangé.
ReShape Lifesciences (NASDAQ: RSLS) hat eine 1-zu-25 Reverse-Aktienzusammenlegung seiner Stammaktien angekündigt, die ab dem 9. Mai 2025 im Handel wirksam wird. Nach der Zusammenlegung werden jeweils 25 ausstehende Stammaktien zu einer Aktie konsolidiert. Das Unternehmen wird anteilige Anpassungen an ausstehenden Warrants, Aktienoptionen und wandelbaren Vorzugsaktien vornehmen. Etwaige Bruchteile von Aktien werden auf die nächste ganze Aktie aufgerundet.
Die Reverse-Split wurde am 1. April 2025 von den Aktionären genehmigt. Der Transferagent des Unternehmens, Equiniti Trust Company, wird Anweisungen zum Umtausch der bestehenden Zertifikate bereitstellen. Die neue CUSIP-Nummer lautet 76090R408. Die Anzahl der genehmigten Aktien gemäß der Satzung des Unternehmens bleibt unverändert.
- Potential compliance with Nasdaq minimum bid price requirements
- May attract institutional investors who have minimum share price requirements
- Reduction in the number of outstanding shares could improve stock marketability
- No fundamental change in company value or market capitalization
- Potential negative market perception of reverse splits
- Transaction costs associated with implementing the reverse split
Effective as of Commencement of Trading on May 9, 2025
IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-25 reverse stock split of the company’s common stock, which will be effective for trading purposes upon the commencement of trading on May 9, 2025. At that time, each 25 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise or conversion price of the company’s outstanding warrants, stock options and convertible preferred stock, in each case in accordance with their terms. Any fractional shares of common stock resulting from the reverse stock split will be rounded up to the nearest whole share. The number of authorized shares of common stock and preferred stock under the company’s certificate of incorporation will not be reduced in connection with the reverse stock split.
The reverse stock split was approved by ReShape Lifesciences’ stockholders at the company’s special meeting of stockholders held on April 1, 2025. ReShape Lifesciences stockholders will receive instructions from the company’s transfer agent, Equiniti Trust Company, LLC, as to procedures for exchanging existing stock certificates for new certificates or book-entry shares. The new CUSIP number for the company’s common stock following the reverse stock split will be 76090R408.
About ReShape Lifesciences Inc.
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
Contacts
ReShape Lifesciences Investor Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com
139996032.1
FAQ
What is the reverse stock split ratio for ReShape Lifesciences (RSLS) and when does it take effect?
How will RSLS reverse stock split affect existing shareholders?
What is the new CUSIP number for RSLS stock after the reverse split?
When did shareholders approve the RSLS reverse stock split?
What happens to fractional shares in the RSLS reverse split?
